Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials.

Funder: laura and john arnold foundationBACKGROUND: Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX ). METHODS: In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung-Knapp-Sidik-Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. RESULTS: A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I2 = 0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. CONCLUSIONS: Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care

Innovation Dynamics in Multipartneralliance Teams: A Focus on Human Resource Management Fit

We explore the innovation dynamics in multipartner-alliance teams (MA teams), a particularly complex type of teams. MA teams are temporary project teams composed of members from different partners and are in charge of attaining innovation. In particular, we focus on the potential contributions of human resource management (HRM) fit on the creation of a proper MA team climate for innovation. We address the necessity of reconceptualizing the notion of HRM fit from a holistic view, offering a new multi-level conceptualization. At the partner-level, we include the two traditional dimensions of HRM fit (vertical fit and horizontal fit); at the alliance-level, we include a new dimension (?relational fit?). Our arguments allow us to conclude that the power of the HRM fit at the partner-level is reinforced/undermined depending on the synergistic effects of the combination of the partners? sets of alliance-specific HRM practices for a particular MA team. Some directions for further work are suggested.Multipartner alliances, team, fit, Human Resources Management, innovation

Evaluation of the lung cancer screening program

Continuando con la l?nea de investigaci?n de cribados, Avalia-t eval?a en este informe la efectividad cl?nica, seguridad y eficiencia del cribado de c?ncer de pulm?n. El informe incluye adem?s, la evaluaci?n del grado de cumplimiento de los requisitos para la implementaci?n de programas de cribado poblacionales en la cartera de servicios del sistema nacional de salud espa?ol, Con todo, no se debe iniciar el cribado de una enfermedad si las ventajas de su detecci?n precoz para la poblaci?n diana no est?n claramente definidas y sin que existan garant?as de un adecuado diagn?stico, seguimiento y tratamiento de todas las personas identificadas por parte del sistema sanitario.Continuando coa li?a de investigaci?n de cribados, Avalia-t aval?a neste informe a efectividade cl?nica, seguridade e eficiencia do cribado de cancro de pulm?n. O informe incl?e ademais, a avaliaci?n do grao de cumprimento dos requisitos para a implementaci?n de programas de cribado poboacionais na carteira de servizos do sistema nacional de sa?de espa?ol, Con todo, non se debe iniciar o cribado dunha enfermidade se as vantaxes da s?a detecci?n precoz para a poboaci?n diana non est?n claramente definidas e sen que existan garant?as dun adecuado diagn?stico, seguimento e tratamento de todas as persoas identificadas por parte do sistema sanitario